| 1. |
David Fidock (Columbia) |
Resistance generation |
OSM-S-106 and Pro (no inactive enantiomer) |
π΅ Processing results |
| 2. |
TCGLS (MMV) |
Pf3D7, Dd2, HepG2, ADME Tier 1 |
The 6 compounds: 106-Pro, 106-Pro-D, 106-ILeu, 106-Phe, 106-Lys, 106-Ser |
π’ Data available |
| 3. |
TCGLS (MMV) |
PRR |
106-Pro |
π’ Data available |
| 4. |
TCGLS (MMV) |
CaCo-2 permeability |
106-Pro and 106-Phe |
π΅ Shipped. Awaiting results |
| 5. |
Andrew Plater & Beatriz Baragana (Dundee) |
Enzymatic pECβ
β inhibition |
The 6 compounds: 106-Pro, 106-Pro-D, 106-ILeu, 106-Phe, 106-Lys, 106-Ser; And plus: 106, 106-Gly |
π’ Data available |
| 6. |
Jacquin Niles (MIT) |
Testing against panel and cKD parasites |
|
π΄ Follow-up made |
| 7. |
SSGCID |
Diffraction (structural studies) |
106-Pro |
π’ Data available |
| 8. |
Yoga & Amit Sharma (ICGEB Delhi) |
Biochemical potency assays |
106, 106-Pro, 106-Pro-D, 106-Phe, 106-Lys |
π΅ Shipped. Awaiting results π’ Lys data available |
| 9. |
Conner Payne & Ralph Mazitschek (HSPH) |
TR-FRET assay |
106 and 106-Pro |
π’ Data available |
| 10. |
Amanda Lukens & Dyann Wirth (HSPH) |
Cellular profiling against ProRS mutants |
106, 106-Pro and 106-Pro-D |
π’ 106 and 106-Pro data available. π΅ Awaiting 106-Pro-D result |
| 11. |
Stanley Xie & Leann Tilley (UoM) |
eIF2Ξ± phosphorylation |
106-Pro and 106-Pro-D |
π’ Data available |
| 12. |
Rebecka (Barcelona) |
Solubility testing |
106, 106-Pro, 106-ala, 106-ILeu, 106-Leu, 106-Val, 106-Phe, 106-Asp |
π’ Data available; contact Rebecka |
| 13. |
UKHSA |
Biochemical potency assays against M. avium |
106, 106-Pro, 106-ala, 106-ILeu, 106-Leu, 106-Val, 106-Phe, 106-Asp |
π’ Data available |
| 14. |
London Metropolitan University |
Elemental analysis |
106-Pro (Bot, Salt and neutralised) |
π΄ coordinating |
π΅ In Progress/ π’ Completed/ π΄ Pending
vs. Plasmodium falciparum:
Others:
XRSProject_Summary_May2025.docx